Charles Farkas - CNMD / CONMED Corporation - Insider Trade Report

Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Charles Farkas in CNMD / CONMED Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2017-07-05	157	50.7800	157	50.7800	7,972	352	76.4300	4,028	50.52

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Charles Farkas in CNMD / CONMED Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2025-09-12	1,103	53.5350	1,103	53.5350	59,049	7	50.0100	-3,888	-6.58
2025-09-12	897	53.5120	897	53.5120	48,000
2025-05-05	4,000	56.9420	4,000	56.9420	227,768

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Transaction History